Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 1 1

Status

Completed 74Terminated 15Recruiting 7Unknown 2Suspended 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 21Gastrointestinal 15Other solid neoplasm 14Lymphoid 14Genitourinary 11CNS 11Breast 10Tumor-Agnostic 9Thoracic 9Gynecologic 8Dermatologic 7Sarcoma 6Myeloid 6Head & Neck 4Plasma cell 1Endocrine 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

TAK-243 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Suspended × Classical hematology × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡